西妥昔单抗联合维莫非尼治疗巨大基底细胞鳞癌完全缓解 1 例
Complete response of a large basosquamous carcinoma following treatment with cemiplimab and vismodegib.
机构信息
Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA
Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
出版信息
BMJ Case Rep. 2023 Jul 14;16(7):e251273. doi: 10.1136/bcr-2022-251273.
The anti-PD-1 antibody cemiplimab has demonstrated effectiveness in the setting of locally advanced basal cell carcinoma (BCC) and squamous cell carcinoma. We describe a case of a large, locally invasive basosquamous carcinoma, an aggressive type of BCC, invading the left sternocleidomastoid muscle with near compression of the left internal jugular vein producing a severe anaemia secondary to ulceration and chronic blood loss. The patient was initially started on vismodegib monotherapy but failed to respond. He was then started on cemiplimab in addition to vismodegib. Improvement was noted after one cycle. After 21 cycles of cemiplimab, the left shoulder ulcerated lesion was completely re-epithelialised. He remains in complete remission after 31 cycles of cemiplimab in addition to vismodegib.
抗 PD-1 抗体西米普利单抗在局部晚期基底细胞癌（BCC）和鳞状细胞癌的治疗中显示出有效性。我们描述了一例大型局部侵袭性基底鳞状细胞癌，这是一种侵袭性 BCC 类型，侵犯左侧胸锁乳突肌，几乎压迫左侧颈内静脉，导致溃疡和慢性失血引起严重贫血。患者最初开始接受维莫德吉单药治疗，但未产生应答。随后，他开始联合西米普利单抗进行治疗。在一个周期后观察到改善。在接受 21 个周期的西米普利单抗治疗后，左侧肩部溃疡性病变完全重新上皮化。在接受西米普利单抗联合维莫德吉治疗 31 个周期后，他仍处于完全缓解状态。
Zotero 插件